# Pennant Group, Inc.

**PNTG**

Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001766400

**D**

**fourth fifth of 367 graded peers in healthcare**

rank 262 of 367; percentile 71.3; sampling error 2.5 points; lower is stronger

A B C D E

**D, the sloth**



## Scoreboard


| | |
|---|---|
| **Profitability** | D<br>percentile 75.4 |
| **Solvency** | C/D<br>percentile 58.6 |
| **Growth and financing** | B<br>percentile 32.3 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $968.2M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: short runway, distress, fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 26, 2026<br>262 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026 |
| **Last close** | $36.10<br>2026-11-13; market equity $1.3B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 26, 2026*

The Pennant Group, Inc. is a leading provider of high-quality healthcare services to patients, residents, and clients of all ages, including the growing senior population, in the United States. We strive to be the provider of choice in the communities we serve through our innovative operating model and unique core values. As of December 31, 2025, we operate in multiple lines of business, including home health, hospice, and senior living services across Alabama, Arizona, California, Colorado, Georgia, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin and Wyoming.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 75.4** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (2.3%) | (6.6%) | 75.4 | 799 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 58.6** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | 1.45 | (0.31) | 30.7 | 743 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 1.14x | 2.96x | 86.5 | 825 | 2025-12-31 | |
| **Growth and financing, sleeve percentile 32.3** | | | | | | |
| Revenue growth, three-year compound | 26.0% | 10.1% | 24.9 | 411 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | 6.5% | 37.1% | 65.0 | 104 | 2025-12-31 | |
| Asset growth, three years | 23.7% | 2.3% | 18.5 | 693 | 2025-12-31 | |
| Net share issuance, one year | 0.7% | 2.4% | 20.9 | 627 | 2026-02-23 | |

## Among 367 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 257 | Iridex Corp. (IRIX) | 69.9 | D | fortress balance sheet |
| 258 | Lyell Immunopharma, Inc. (LYEL) | 70.2 | D | dilution, degenerate inputs |
| 259 | Bioventus Inc. (BVS) | 70.5 | D | |
| 260 | Regeneron Pharmaceuticals, Inc. (REGN) | 70.8 | D | |
| 261 | uniQure N.V. (QURE) | 71.0 | D | fortress balance sheet |
| 262 | Pennant Group, Inc. (PNTG) | 71.3 | D | |
| 263 | Bausch & Lomb Corp. (BLCO) | 71.6 | D | |
| 264 | Bausch Health Companies Inc. (BHC) | 71.9 | D | |
| 265 | 3M Co. (MMM) | 72.1 | D | |
| 266 | Cumberland Pharmaceuticals Inc. (CPIX) | 72.4 | D | |
| 267 | Elanco Animal Health Inc. (ELAN) | 72.7 | D | |

## What the price implies

*at the 2026-11-13 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 57.7% | (1.5%) | 80 |
| Distance from 52-week high | (18.1%) | (32.0%) | 63 |
| EBIT to enterprise value | not computable | (1.8%) | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Free cash flow yield | 2.9% | (1.0%) | 69 |
| Book value to price | 0.33 | 0.29 | 54 |
| Sales to price | 0.75 | 0.29 | 76 |
| Composite equity issuance, five years | 21.8% | 19.1% | 51 |
| Relative strength against the sector, log excess return | 0.29 | (0.18) | 80 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 11 (10-Q received Nov 4, 2026) |
| Median daily dollar volume, 63 sessions | $11.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | $29.6M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $48.3M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 3 | assets | us-gaap:Assets | $968.2M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 4 | assets | us-gaap:Assets | $679.5M | 2024-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 5 | current assets | us-gaap:AssetsCurrent | $167.4M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $147.3M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $86.8M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | $51.9M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 9 | book equity | us-gaap:StockholdersEquityIncludingPortionAttributableT... | $374.3M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 10 | liabilities | us-gaap:Liabilities | $593.9M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | $25.2M | 2023-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 12 | interest expense | us-gaap:InterestExpense | $5.9M | 2023-12-31 | 2024-02-28 | 10-K | 24-000022 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $947.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $695.2M | 2024-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $544.9M | 2023-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $473.2M | 2022-12-31 | 2025-02-27 | 10-K | 25-000024 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $12.0M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $39.3M | 2024-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $9.0M | 2024-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $33.1M | 2023-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $8.1M | 2023-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $9.0M | 2022-12-31 | 2025-02-27 | 10-K | 25-000024 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $14.2M | 2022-12-31 | 2025-02-27 | 10-K | 25-000024 |
| 24 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $8.5M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 25 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $45.6M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 26 | income tax | us-gaap:IncomeTaxExpenseBenefit | $11.9M | 2025-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 27 | current assets | us-gaap:AssetsCurrent | $122.9M | 2024-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 28 | current liabilities | us-gaap:LiabilitiesCurrent | $101.7M | 2024-12-31 | 2026-02-26 | 10-K | 26-000014 |
| 29 | assets | us-gaap:Assets | $539.7M | 2023-12-31 | 2025-02-27 | 10-K | 25-000024 |
| 30 | assets | us-gaap:Assets | $512.1M | 2022-12-31 | 2024-02-28 | 10-K | 24-000022 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 34,663,118 | 2026-02-23 | 2026-02-26 | 10-K | 26-000014 |
| 32 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 34,429,989 | 2025-02-24 | 2025-02-27 | 10-K | 25-000024 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.